NRX Pharmaceuticals posts Q3 loss and reports first revenue after Dura Medical acquisition
I'm PortAI, I can summarize articles.
NRX Pharmaceuticals reported a Q3 2025 operational loss of $4.0 million, up from $3.0 million in Q3 2024, due to increased R&D and administrative costs. The company recorded its first revenue of $0.2 million post-Dura Medical acquisition. Cash reserves are expected to support operations through Q2 2026. Future revenue growth is anticipated from further acquisitions and expansion of HOPE clinics in Florida.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments